European Patent Office approves Corcept's use of GR-II antagonists for depression

By Lisa Kerner

Erie, Pa., Feb. 6 - Corcept Therapeutics Inc. said the European Patent Office has allowed the company's patent covering the use of GR-II antagonists to treat psychotic major depression, which is characterized by severe depression, by delusions and/or hallucinations.

The patent is exclusively licensed to the Corcept by Stanford University, according to a company news release.

Officials said the patent application had been challenged in 2004 by Akzo Nobel. Corcept filed its rebuttal with the EPO in 2005.

Corcept's lead product, Corlux, is in phase 3 trials for the treatment of psychotic major depression.

Menlo Park, Calif.-based Corcept develops drugs for the treatment of severe psychiatric and neurological diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.